Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 11, 2014, Pages 1639-1648

  Nagy, Béla ^a   Bhattoa, Harjit Pal ^a   Steiber, Zoltán ^a   Csobán, Mária ^a   Szilasi, Mária ^a   Méhes, Gábor ^a   Müller, Mónika ^b   Lázár, József ^c   Kappelmayer, János ^a   Antal Szalmás, Péter ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Adware Research Kft   (Hungary)

^c Biosystem International Hungary Co   (Hungary)

Author keywords

HE4; lung cancer; non small cell lung cancer (NSCLC); small cell lung cancer (SCLC); tumor marker

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; HUMAN EPIDIDYMIS PROTEIN 4; NEURON SPECIFIC ENOLASE; THYMIDINE KINASE; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER; PROTEIN; WFDC2 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; SMOKING; TUMOR VOLUME; VERY ELDERLY; AREA UNDER THE CURVE; BLOOD; CANCER STAGING; COHORT ANALYSIS; ELECTROCHEMICAL ANALYSIS; GLOMERULUS FILTRATION RATE; IMMUNOASSAY; LUMINESCENCE; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CA-125 ANTIGEN; COHORT STUDIES; ELECTROCHEMICAL TECHNIQUES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOASSAY; LUMINESCENT MEASUREMENTS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEINS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84906339554     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0041     Document Type: Article

References (43)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-7
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94
3. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008;83:355-67
4. Humphrey LL, Teutsch S, Johnson M, U.S. Preventive Services Task Force. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2004;140:740-53
5. Kulpa J, Wójcik E, Reinfuss M, Kołodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002;48:1931-7
6. Hatzakis KD, Froudarakis ME, Bouros D, Tzanakis N, Karkavitsas N, Siafakas NM. Prognostic value of serum tumor markers in patients with lung cancer. Respiration 2002;69:25-9
7. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2) is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002;21:2768-73
8. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700
9. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847-53
10. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6
11. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100:1315-9
12. Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem 2011;57:1534-44
13. Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011;118:280-8
14. Macuks R, Baidekalna I, Donina S. An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions. Tumour Biol 2012;33:1811-7
15. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol 2012;206:351.e1-8
16. Nagy B Jr, Krasznai ZT, Csoban M, Antal-Szalmás P, Hernádi Z, Kappelmayer J. The emerging value of HE4 in the discrimination of ovarian cancer from other malignant and benign pelvic masses [abstract]. Clin Chem Lab Med 2011;49(Suppl 1):S261
17. Bingle L, Cross SS, High AS, Wallace WA, Rassl D, Yuan G, et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res 2006;7:61-71
18. Tokuishi K, Yamashita S, Ohbo K, Kawahara K. Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma. Tumour Biol 2012;33:103-9
19. Yamashita S, Tokuishi K, Hashimoto T, Moroga T, Kamei M, Ono K, et al. Prognostic significance of HE4 expression in pulmonary adenocarcinoma. Tumour Biol 2011;32:265-71
20. Iwahori K, Suzuki H, Kishi Y, Fujii Y, Uehara R, Okamoto N, et al. Serum HE4 as a diagnostic and prognostic marker for lung cancer. Tumour Biol 2012;33:1141-9
21. Yamashita S, Tokuishi K, Moroga T, Yamamoto S, Ohbo K, Miyahara S, et al. Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression. Tumour Biol 2012;3:2365-70
22. Anastasi E, Granato T, Marchei GG, Viggiani V, Colaprisca B, Comploj S, et al. Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol 2010;31:411-5
23. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:706-14
24. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266
25. Oremek GM, Sauer-Eppel H, Bruzdziak TH. Value of tumour and inflammatory markers in lung cancer. Anticancer Res 2007;27:1911-5
26. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012;76:138-43
27. Molina R, Filella X, Auge JM. Tumour markers in lung cancer. Eur Oncol Dis 2006;1:106-9
28. Stieber P, Hatz R, Holdenrieder S, Molina R, Nap M, von Pawel J, et al. National Academy of Clinical Biochemistry Guidelines for the use of tumor markers in lung cancer. NACB: practice guidelines and recommendations for use of tumor markers in the clinic. Lung Cancer 2006. Available from: http://www.aacc.org/SiteCollectionDocuments/NACB/LMPG/tumor/chp3p-lung. pdf
29. Yu S, Yang HJ, Xie SQ, Bao YX. Diagnostic value of HE4 for ovarian cancer: a meta-analysis. Clin Chem Lab Med 2012;50: 1439-46
30. Kirchhoff C. Molecular characterization of epididymal proteins. Rev Reprod 1998;3:86-95
31. Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, et al. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med 2012;50: 2181-8
32. Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med 2012;50:2189-98
33. Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC Jr, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 2012;206:349.e1-7
34. Nagy B Jr, Krasznai ZT, Balla H, Csobán M, Antal-Szalmás P, Hernádi Z, et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem 2012;49:377-80
35. Gizzo S, Ancona E, Saccardi C, D'Antona D, Nardelli GB, Plebani M. Could kidney glomerular filtration impairment represent the "Achilles heel" of HE4 serum marker? A possible further implication. Clin Chem Lab Med 2014;52:e45-6
36. Li X, Asmitananda T, Gao L, Gai D, Song Z, Zhang Y, et al. Biomarkers in the lung cancer diagnosis: a clinical perspective. Neoplasma 2012;59:500-7
37. Giovanella L, Piantanida R, Ceriani L, Bandera M, Novario R, Bianchi L, et al. Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis. Int J Biol Markers 1997;12:22-6
38. Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res 2001;21:3085-92
39. Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, et al. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer 2012;131:911-23
40. Mrázová V, Mocák J, Varmusová E, Kavková D, Bednárová A. Use of multidimensional data analysis for prediction of lung malignity. J Pharm Biomed Anal 2009;50:210-5
41. Lee HJ, Kim YT, Park PJ, Shin YS, Kang KN, Kim Y, et al. A novel detection method of non-small cell lung cancer using multiplexed bead-based serum biomarker profiling. J Thorac Cardiovasc Surg 2012;143:421-7
42. Farlow EC, Vercillo MS, Coon JS, Basu S, Kim AW, Faber LP, et al. A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer 2010;103:1221-8
43. Liu W, Yang J, Chi PD, Zheng X, Dai SQ, Chen H, et al. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis. Int J Tuberc Lung Dis 2013;17:1346-53.